---
title: "Jejunal Adenocarcinoma Case Study: Callie"
description: With surgery and FidoCure® therapy, Callie is alive and well almost 20 months after her initial diagnosis of jejunal adenocarcinoma.
image: https://blog.fidocure.com/hubfs/IMG_1085-1.jpg
---
## Jejunal Adenocarcinoma Case Study: Callie
Jejunal Adenocarcinoma Case Study: Callie
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
[Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
# Jejunal Adenocarcinoma Case Study: Callie
[Dr. Dorothy Jackson Girimonte](https://blog.fidocure.com/fidocure-blog/author/dr-dorothy-jackson-girimonte)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/fidocure-r-case-study-callie-augur) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/fidocure-r-case-study-callie-augur) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/fidocure-r-case-study-callie-augur)
#### With surgery and FidoCure® therapy, Callie is alive and well almost 20 months after her initial diagnosis of jejunal adenocarcinoma.
#### History and Initial Therapy
Callie Augur, a 10-year-old female spayed German Shepherd, was diagnosed with jejunal adenocarcinoma in May 2021. She was initially seen for a one week history of vomiting and anorexia. Her bowel movements began to decrease in frequency and quantity. Abdominal radiographs and a pneumocolonogram were performed. Both were concerning for segmental enteropathy and small intestinal obstruction.
She was then seen by the Surgery department, and a jejunal mass was excised. Biopsy was diagnostic for a transmural adenocarcinoma with a mitotic count of 12. Neoplastic cells did extend into the submucosa and smooth muscle through the serosa and into the attached mesentery. However, the mass was considered completely excised. Given the risk of disease progression, additional therapy was recommended.
#### FidoCure® Analysis
Tissue from Callie’s intestinal tumor was sent for genomic (DNA) sequencing. Genomic analysis revealed alterations of K-RAS and P53.
K-RAS is a member of the RAS family of proteins primarily involved in regulating cell division. It belongs to a class of genes known as oncogenes, which play important roles in cell division, cell differentiation, and apoptosis. Activation of K-RAS or N-RAS oncogenic variants in canine tumors can activate the RAS/RAF/MAP kinase signaling pathway and downstream targets ERK1/2 and AKT. In vitro this is correlated with sensitivity to the MEK1/2 inhibitor Trametinib. Pre-clinical data suggest that one mechanism of adaptive resistance in RAS family mutant cancers exposed to MEK inhibition is enhanced activation of AKT/mTOR. Thus, a potential strategy to thwart this mechanism and sustain greater benefit may be combinatorial inhibition of MEK and mTORC1/2 targets.
TP53 encodes a protein called tumor protein p53 which has become one of the most well published tumor suppressor genes in human and canine cancer. This protein helps to regulate cell growth and damaged cells by controlling signals for pausing the cell cycle and cell death.
#### FidoCure® Treatment
Based on the mutation profile, a combination of trametinib (MEK inhibitor) and rapamycin (mTOR) inhibitor were recommended. Callie was first started on trametinib at a 0.025 mg/kg/day dose in July 2021. She was tolerating that well, so rapamycin was started at a dose of 0.1 mg/kg/day in September 2021. Callie was rechecked every 4-6 weeks initially for bloodwork and did well with no concerns to report. She was restaged approximately every 3 months for thoracic radiographs and abdominal ultrasound.
Callie was last seen in July 2022 and was doing well at home. An ultrasound was performed, and there was no evidence of disease recurrence or metastasis. Given how well she has done on therapy, her rechecks were spread out to every 2 months.
#### Conclusion
With a combination of surgery and targeted therapy, Callie continues to do well almost 20 months following her initial diagnosis of jejunal adenocarcinoma.
Intestinal adenocarcinoma has a high metastatic rate, up to 70% in some studies. Reported median survival time with surgery alone is 10 months with some studies reporting 15 months for those with no evidence of metastatic disease at the time of diagnosis. The role of chemotherapy is relatively unknown for intestinal adenocarcinoma. Further research is needed to determine the role targeted therapy can play in delaying recurrence and/or metastasis.
#### What Callie’s Oncologist Says:
> “Because we know that Callie's tumor displayed some concerning characteristics, including invasion into the submucosa, smooth muscle, through the serosa and attached mesentery. For this reason, I was concerned she was at high risk of metastasis since transcoelomic metastasis does occur with this tumor. Chemotherapy has not shown any survival benefit, so I recommended trying targeted therapies if her tumor exhibited mutations via Fidocure.”
#### Dr. Dorothy Jackson Girimonte
Dr. Dorothy Jackson Girimonte DVM, Diplomate ACVIM (Oncology), CVA Board certified in Medical Oncology 2015
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/what-every-veterinary-oncologist-needs-to-know-about-cancer-genomics)
[Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
### [What Every Veterinary Oncologist Needs to Know About Cancer Genomics](https://blog.fidocure.com/fidocure-blog/what-every-veterinary-oncologist-needs-to-know-about-cancer-genomics)
Genomics is fast becoming an essential part of veterinary oncology. It touches upon all aspects of practice, from diagnostics to therapeutics. Genetic information can be...
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Read More](https://blog.fidocure.com/fidocure-blog/what-every-veterinary-oncologist-needs-to-know-about-cancer-genomics)
[](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu)
[Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
### [Thyroid Carcinoma Case Study: Lulu](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu)
#### After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary...
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Read More](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Dr. Dorothy Jackson Girimonte",
"url" : "https://blog.fidocure.com/fidocure-blog/author/dr-dorothy-jackson-girimonte"
},
"dateModified" : "2023-05-06T12:54:45.847Z",
"datePublished" : "2023-04-25T20:18:09.000Z",
"headline" : "Jejunal Adenocarcinoma Case Study: Callie",
"image" : [ "https://blog.fidocure.com/hubfs/IMG_1085-1.jpg" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/fidocure-r-case-study-callie-augur",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```